Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 17/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 17/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 17/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16166392 | 0.91 | ADRA1D (0.32) | ADRA1DADRA1AADRA1BDRD2DRD1 | |
| SCHEMBL17502986 | 0.88 | MEN1 (0.33) | ADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL16166560 | 0.88 | MEN1 (0.33) | ADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL16166451 | 0.84 | KDM4E (0.33) | ADRA1DADRA1AADRA1B | |
| SCHEMBL16171297 | 0.84 | ADRA1D (0.35) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL17516013 | 0.75 | ADRA1D (0.34) | ADRA1DADRA1AADRA1BADRB2HTR1A | |
| SCHEMBL16166144 | 0.75 | CYP11B2 (0.33) | ADRA1DADRA1AADRA1B | |
| SCHEMBL16166498 | 0.71 | ADRA1D (0.33) | ADRA1DADRA1AADRA1BLMNASMN1; SMN2 | |
| SCHEMBL16166555 | 0.69 | ADRA1D (0.33) | ADRA1DADRA1AADRA1BLMNAADRB2 | |
| SCHEMBL16166556 | 0.69 | ADRA1D (0.33) | ADRA1DADRA1AADRA1BLMNAADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | claimed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | claimed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | claimed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | claimed |
| CN-105102429-A | N-haloalkylindoline intermediates, process and use in preparation of silodosin and derivatives thereof | MANKIND RES CT | 2015-11-25 | — | — | CN | claimed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | claimed |
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2019-03-26 | — | — | US | disclosed |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2018-04-26 | — | — | US | disclosed |
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | disclosed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | disclosed |
| CN-105102429-A | N-haloalkylindoline intermediates, process and use in preparation of silodosin and derivatives thereof | MANKIND RES CT | 2015-11-25 | — | — | CN | disclosed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | ADRA1D, ADRB1, ADRA1A | ADRA1D 1/4885ADRA1A 3/4885ADRA1B 5/4885 |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885 |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.